ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Astellas Pharma, Inc.

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Gross Profit1,002.94B9,224.49M
Operating income281,106M2,585.45M
Income before tax245,350M2,256.59M
Net income195,411M1,797.28M
Diluted EPS104.070.95
Dividends Per Share400.36
Total Assets2,318.16B21,473.39M
Total liabilities1,028.99B9,531.65M
Total equity1,289.16B11,941.71M
Operating cash flow224,060M2,060.78M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 1,372.70B 1,311.66B 1,300.31B 1,306.34B 1,300.84B
Gross Profit 994,723M 955,325M 970,228M 979,086M 1,002.94B
Operating income 270,577M 276,419M 271,241M 280,141M 281,106M
Income before tax 261,770M 281,769M 218,113M 248,967M 245,350M
Net income 193,687M 218,701M 164,679M 222,265M 195,411M
EBITDA 339,765M 340,210M 336,104M 343,599M 347,502M
Diluted EPS 89.62 103.55 81.02 114.94 104.07
Dividends Per Share 32 34 36 38 40
Total Assets 1,799.33B 1,814.07B 1,858.20B 1,897.64B 2,318.16B
Total liabilities 540,129M 540,614M 583,608M 639,252M 1,028.99B
Total equity 1,259.20B 1,271.81B 1,268.28B 1,258.39B 1,289.16B
Operating cash flow 316,534M 237,230M 314,463M 261,428M 224,060M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 11,431.18M 12,112.80M 11,732.27M 11,780.07M 11,964.43M
Gross Profit 8,283.53M 8,822.11M 8,754.00M 8,828.97M 9,224.49M
Operating income 2,253.22M 2,552.63M 2,447.30M 2,526.19M 2,585.45M
Income before tax 2,179.88M 2,602.04M 1,967.95M 2,245.07M 2,256.59M
Net income 1,612.92M 2,019.63M 1,485.83M 2,004.28M 1,797.28M
EBITDA 2,829.38M 3,141.72M 3,032.54M 3,098.42M 3,196.13M
Diluted EPS 0.74 0.95 0.73 1.03 0.95
Dividends Per Share 0.26 0.31 0.32 0.34 0.36
Total Assets 16,009.05M 16,279.92M 17,472.54M 17,144.58M 21,473.39M
Total liabilities 4,805.63M 4,851.60M 5,487.61M 5,775.41M 9,531.65M
Total equity 11,203.42M 11,413.53M 11,925.61M 11,369.16M 11,941.71M
Operating cash flow 2,635.93M 2,190.74M 2,837.28M 2,357.44M 2,060.78M

Valuation Measures

Mar 2020
Operating margin21.60%
Profit margin15.02%

Key executives

  • President, CEO & Representative Director: Kenji Yasukawa
  • Head-Business Administration & Compliance: Fumiaki Sakurai
  • Representative Director & Vice President: Naoki Okamura
  • Senior VP-Product & Portfolio Strategy: Claudia Mitchell
  • Senior Executive Officer & General Manager-Sales: Nobuaki Tanaka


  • Nomura Asset Management Co., Ltd. (5.8%)
  • Nippon Life Insurance Co. (3.4%)
  • BlackRock Fund Advisors (3.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.0%)
  • Nikko Asset Management Co., Ltd. (2.9%)
  • The Vanguard Group, Inc. (2.8%)
  • Daiwa Asset Management Co. Ltd. (2.6%)
  • Norges Bank Investment Management (1.9%)
  • Wellington Management Co. LLP (1.7%)
  • BlackRock Japan Co., Ltd. (1.5%)

Contact Details

  • Website:
  • Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
  • Phone: +81.3.3244.3000

Related Companies

  • Xyphos Biosciences, Inc.
  • Astellas Pharma, Inc. /Agensys Research Facilities/
  • Astellas Pharma, Inc. /16 Long Listed Products/
  • Astellas Farma Colombia
  • Astellas Pharma Director Incentive Plan
  • Quethera Ltd.
  • PT Astellas Pharma Indonesia
  • Astellas Pharma ZAO
  • Astellas Pharma ilac Ticaret ve Sanayi AS
  • Astellas Pharma Hong Kong Co. Ltd.
  • Astellas Pharma India Pvt Ltd.
  • Astellas Pharma Thailand Co. Ltd.
  • Astellas Pharma Australia Pty Ltd.
  • Astellas Pharma Singapore Pte Ltd.
  • Astellas Pharma Tech Co., Ltd.
  • Audentes Therapeutics, Inc.
  • Mitobridge, Inc.
  • Astellas Pharma China, Inc.
  • Perseid Therapeutics LLC
  • GPDC Partnership
  • Astellas Pharma Philippines, Inc.
  • Astellas Pharma Co. Ltd.
  • Astellas Pharma Canada, Inc.
  • Fujisawa Taiwan Co. Ltd.
  • Astellas Pharma SARL
  • Astellas Pharma Netherlands
  • Yamanouchi Health & Beauty Co. Ltd.
  • Yabrofarma Lda.
  • Fujisawa Ireland Ltd.
  • Astellas Pharma Korea, Inc.


  • AstraZeneca PLC
  • Roche Holding AG
  • Hanmi Pharmaceutical Co., Ltd.
  • AbClon, Inc.
  • LegoChem Biosciences, Inc.
  • Ipsen SA
  • Adaptimmune Therapeutics PLC Sponsored ADR
  • Bicycle Therapeutics Plc Sponsored ADR
  • Arcus Biosciences, Inc.
  • Immunomedics, Inc.
  • Mirati Therapeutics Inc.
  • Antares Pharma, Inc.
  • MedPacto, Inc.
  • NantKwest, Inc.
  • Agenus Inc.
  • CrystalGenomics Inc.
  • DongKoo Bio & Pharm Co. Ltd.
  • Constellation Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Sophiris Bio Inc.
  • Urovant Sciences Ltd.
  • Agios Pharmaceuticals, Inc.
  • Biophytis SA
  • GlycoMimetics, Inc.
  • Scholar Rock Holding Corp.
  • Summit Therapeutics PLC Sponsored ADR
  • Aravive, Inc.
  • Checkpoint Therapeutics, Inc.
  • ERYTech Pharma SA
  • LogicBio Therapeutics, Inc.
Last Updated on 14 Jul, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media